- Home
- SLBT vs AVTX Comparison
SLBT vs AVTX Comparison
Compare SLBT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLBT | AVTX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | Taiwan | United States |
| Employees | N/A | 33 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.1M | 801.8M |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SLBT | AVTX |
|---|---|---|
| Price | $1.66 | $15.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $44.08 |
| AVG Volume (30 Days) | 108.5K | ★ 926.6K |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $1.42 | $12.51 |
| 52 Week High | $6.25 | $24.27 |
Technical Indicators
Market Signals| Indicator | SLBT | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.86 | 37.58 |
| Support Level | N/A | $15.11 |
| Resistance Level | $3.36 | $20.54 |
| Average True Range (ATR) | 0.18 | 0.82 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 32.89 | 32.95 |
Price Performance
Historical ComparisonAbout SLBT SL Science Holding Limited Ordinary Shares
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.